Drug product and process development teams working on spray‑dried dispersions (SDDs) for tablets, capsules, granules, and DPIs, especially when scaling across sites or CDMOs.​

SDD particles have complex, hollow morphologies that strongly influence dissolution, stability, tablet strength, and ultimately bioavailability and yield.​

Traditional tools cannot quantify these structures at scale, so teams only see the business impact as variability: failed dissolution tests, tablet defects, site‑to‑site differences, clinical surprises.